- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Myelodysplastic Syndrome (MDS) - High and Intermediate Risk
Total 2965 results
-
Forma Therapeutics, Inc.RecruitingVery Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-RUnited States, France, Canada, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMyelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1United States
-
Celgene CorporationCompletedLow- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)United States
-
Assistance Publique - Hôpitaux de ParisUnknownInfection | Risk Factors | Myelodysplastic Syndrome (MDS) | IPSS High RiskFrance
-
Novartis PharmaceuticalsTerminated
-
Novartis PharmaceuticalsActive, not recruitingAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Spain, Singapore, Australia, Germany, Italy, Finland, United States
-
University of UlmTerminatedAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Germany
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedMyelodysplastic Syndrome | MDS | Low to Intermediate-1 MDS | Non-deletion 5qUnited States
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom
-
GWT-TUD GmbHAmsterdam UMC, location VUmc; BerGenBio ASA; Groupe Francophone des MyelodysplasiesCompletedAcute Myeloid Leukemia | High-risk Myelodysplastic Syndrome | Low-risk Myelodysplastic SyndromeGermany, Netherlands, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
Merck Sharp & Dohme LLCCompletedMyelodysplastic Syndromes | Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Low to Intermediate-1 MDSUnited States, France
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Novartis PharmaceuticalsCompletedAML and High Risk MDSGermany, Italy, France, Netherlands, United States, Australia, Japan
-
SCRI Development Innovations, LLCNovartis PharmaceuticalsTerminated
-
PersImmune, IncUniversity of California, San DiegoUnknown
-
Ascentage Pharma Group Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic SyndromeUnited States
-
Opna-IO LLCCompletedHigh-risk Myelodysplastic Syndrome (MDS) | Relapsed Acute Myeloid Leukemia (AML) | Refractory Acute Myeloid Leukemia (AML)United States
-
Schrödinger, Inc.RecruitingAcute Myeloid Leukemia | High-Risk and Very High-Risk Myelodysplastic SyndromesUnited States
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
FibroGenAstraZeneca; Astellas Pharma IncTerminatedPrimary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHigh Risk Myelodysplastic SyndromeUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedHigh Risk MDS or AML PatientsUnited States
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
-
Institute of Hematology & Blood Diseases Hospital...Beijing Health Alliance Charitable FoundationRecruitingLower Risk MDS Per IPSS-RChina
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
Central Hospital, Nancy, FranceInserm U954 - N-GERE (Nutrition, Genetics and Exposition to Environmental...UnknownHigh-risk Myelodysplastic Syndromes With Excess BlastsFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk...United States
-
Ginna LaportTerminatedAcute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors | Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase | Myelodysplastic Syndrome (MDS) - High and Intermediate Risk | Non-Hodgkin's Lymphoma (NHL) | Chronic Lymphocytic Leukemia...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2United States
-
Institut fuer anwendungsorientierte Forschung und...University Medical Center GoettingenCompletedMyelodysplastic Syndromes (MDS) | Chromosmal Aberrations | Karyotype Evolution | Rare Abnormalities | Cytogenetic MonitoringGermany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Mixed Phenotype Acute LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Stanford UniversityCelgene CorporationTerminatedLeukemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)United States
-
Prof. Janet DunnKing's College Hospital NHS Trust; University of Manchester; University of Birmingham and other collaboratorsRecruitingMyelodysplastic Syndromes (MDS)United Kingdom
-
Radboud University Medical CenterRecruitingMyelodysplastic Syndromes (MDS)Denmark, Switzerland, Serbia, Austria, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, United Kingdom
-
TakedaWithdrawn
-
TJ Biopharma Co., Ltd.CompletedAcute Myeloid Leukemia (AML) | Myelodysplastic Syndromes(MDS)China
-
Sunnybrook Health Sciences CentrePrincess Margaret Hospital, Canada; Juravinski Cancer CenterUnknownQuality of Life | Myelodysplastic Syndromes (MDS) | Red Blood Cell (RBC) TransfusionsCanada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); CelgeneRecruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated CellsUnited States
-
Peking Union Medical College HospitalUnknownLow/Intermediate Risk-1 MDSChina
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndrome (MDS)United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
-
Amphivena Therapeutics, Inc.CompletedMyelodysplastic Syndrome (MDS)United States
-
CelgeneCompletedMyelodysplastic Syndrome (MDS)China